Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Protagenic Therapeutics ( (PTIX) ) is now available.
On May 21, 2025, Protagenic Therapeutics announced it received $3.1 million from recent warrant exchanges and exercises. This funding will support working-capital needs and advance its drug candidates for stress-related and central-nervous-system disorders, coinciding with its business combination with Phytanix Bio Inc., which expands its drug programs to include stress disorders, epilepsy, and obesity.
Spark’s Take on PTIX Stock
According to Spark, TipRanks’ AI Analyst, PTIX is a Underperform.
Protagenic Therapeutics faces significant financial difficulties, with no revenue and persistent losses. Technical indicators suggest weak market momentum, and the company’s valuation is unattractive due to negative earnings. These factors collectively result in a low overall stock score, reflecting substantial risks and challenges.
To see Spark’s full report on PTIX stock, click here.
More about Protagenic Therapeutics
Protagenic Therapeutics, Inc. is a company focused on pioneering peptide-based therapies for stress-related disorders, operating in the pharmaceutical industry.
Average Trading Volume: 2,123,447
Technical Sentiment Signal: Hold
Current Market Cap: $6.54M
See more insights into PTIX stock on TipRanks’ Stock Analysis page.